Market Place
Sourcing Support
InDex Pharmaceuticals announces expected cash balance per March 31, 2024
19 Jan 2024 //
PR NEWSWIRE
InDex Pharmaceuticals discontinues cobitolimod phase III program
22 Nov 2023 //
PR NEWSWIRE
InDex Pharma has been granted a new patent for cobitolimod in South Korea
20 Oct 2023 //
PR NEWSWIRE
InDex Pharmaceuticals is attending the UEGW 2023 congress
05 Oct 2023 //
PR NEWSWIRE
Positive results from PK study with cobitolimod` selected as one of the best abstracts for presentation
22 Aug 2023 //
PR NEWSWIRE
InDex Pharma has been granted a new patent in Europe for cobitolimod
02 Aug 2023 //
PR NEWSWIRE
Viatris targets ulcerative colitis in Japan with $10M agreement with InDex
01 Jun 2023 //
ENDPTS
InDex Pharmaceuticals announces license agreement with Viatris Japan
31 May 2023 //
PR NEWSWIRE
InDex Pharmaceuticals` investor call at 15:00 CET on June 1
31 May 2023 //
PR NEWSWIRE
Welcome to an InDex Pharmaceuticals business update presentation in Stockholm
26 Apr 2023 //
PR NEWSWIRE
InDex announces positive results from PK study with cobitolimod
15 Mar 2023 //
PR NEWSWIRE
InDex Pharmaceuticals to attend the ECCO 2023 congress
27 Feb 2023 //
PR NEWSWIRE
InDex provides information on PIII program CONCLUDE with cobitolimod
14 Feb 2023 //
PR NEWSWIRE
InDex updates the timeline of the phase III study CONCLUDE with cobitolimod
27 Jan 2023 //
PR NEWSWIRE
Jenny Sundqvist new CEO of InDex Pharmaceuticals
10 Oct 2022 //
PRNEWSWIRE
InDex Pharmaceuticals to exhibit at United European Gastroenterology Week
05 Oct 2022 //
PRNEWSWIRE
InDex Pharma successfully interacts with PMDA for cobitolimod in Japan
16 Aug 2022 //
PRNEWSWIRE
InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe
13 Jul 2022 //
PRNEWSWIRE
Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
28 Apr 2022 //
PRNEWSWIRE
InDex Pharmaceuticals prepares for commercialisation of cobitolimod
14 Mar 2022 //
PRNEWSWIRE
InDex enrols first subject in trial of cobitolimod for ulcerative colitis
08 Dec 2021 //
CLINICALTRIALSARENA
InDex Beings Enrollment in phase III study of cobitolimod in ulcerative colitis
24 Nov 2021 //
PRNEWSWIRE
InDex Pharmaceuticals Holding AB (publ) interim report January - September 2021
23 Nov 2021 //
PRNEWSWIRE
InDex Pharmaceuticals gets new patent for cobitolimod granted in the US
09 Nov 2021 //
PRNEWSWIRE
InDex Pharmaceuticals strengthens the clinical development organization
23 Aug 2021 //
PRNEWSWIRE
InDex Pharmaceuticals conducts PK study with cobitolimod
19 Aug 2021 //
PRNEWSWIRE
InDex first regulatory approval to start the phase III study with cobitolimod
21 Jul 2021 //
PRNEWSWIRE
InDex gets patent for additional DIMS compounds granted in Europe
07 Apr 2021 //
PRNEWSWIRE
InDex gets patent for additional DIMS compounds granted in Europe
06 Apr 2021 //
PRNEWSWIRE
InDex enters agreement with Parexel Biotech for phase III clinical study
30 Mar 2021 //
PRNEWSWIRE
InDex presents at Barclays Global Healthcare Conference
09 Mar 2021 //
PRNEWSWIRE
InDex Pharma results of phase IIb study with cobitolimod Published in Lancet
06 Oct 2020 //
PRNEWSWIRE
The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals`
05 Oct 2020 //
PRNEWSWIRE
InDex to present the successful results of the CONDUCT study at two
24 Aug 2020 //
PRNEWSWIRE
InDex Pharmaceuticals to present the successful results of the CONDUCT study
24 Aug 2020 //
PRNEWSWIRE
InDex Advances Cobitolimod Further Towards Ph III Following Successful
16 Apr 2020 //
PR NEWSWIRE
InDex Pharma receives SEK 2.0 mn grant from Vinnova for pre-clinical devp
31 Mar 2020 //
PHARMABIZ
